FDA announces plan to halt marketing of terfenadine.
D004347:Drug Interactions; D004335:Drug and Narcotic Control / Q000331:legislation & jurisprudence; D006634:Histamine H1 Antagonists / Q000009:adverse effects*; D006801:Humans; D017180:Tachycardia, Ventricular / Q000139:chemically induced; D016593:Terfenadine / Q000009:adverse effects*; D014481:United States; D014486:United States Food and Drug Administration
D006634:Histamine H1 Antagonists; D016593:Terfenadine